BNTX241115P105000
- 1.78
- +0.66+58.93%
BioNTech Newsroom
BioNTech Is Maintained at Hold by TD Cowen
A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $110 to $145
Promising Developments in BioNTech's Oncology Pipeline Drive Buy Rating
BioNTech Price Target Cut to $122.00/Share From $132.00 by TD Cowen
A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $122 to $171
BioNTech SE (BNTX) Receives a Hold From Oppenheimer
Deutsche Bank Sticks to Their Buy Rating for BioNTech SE (BNTX)
BioNTech SE: Strong Financial Performance and Promising Future Justify Buy Rating
BioNTech Is Maintained at Neutral by JP Morgan
BioNTech Analyst Ratings
Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)
CCORF Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $171
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
BioNTech Is Maintained at Hold by TD Cowen
BioNTech Analyst Ratings
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
TD Cowen Maintains BioNTech(BNTX.US) With Hold Rating, Raises Target Price to $132
Cautious Long-term Growth Potential: Yaron Werber's Hold Rating on BioNTech SE
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145